Shilpa Medicare gets USFDA’s approval for Bortezomib for Injection

09 Apr 2019 Evaluate

Shilpa Medicare has received the US Food and Drug Administration’s (USFDA) tentative approval for its ANDA, Bortezomib for Injection, 3.5mg/vial. Bortezomib for Injection, 3.5mg/vial is a generic equivalent of reference listed drug (RLD), VELCADE used in the treatment of patients with multiple myeloma and Mantle Cell Lymphoma as recommended in the label approved by USFDA.

According to IQVIA MAT Q4 2018 data, the US market for Bortezomib for Injection 3.5 mg/vial is approximately $609 million.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare Share Price

300.20 13.00 (4.53%)
03-Feb-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1702.80
Dr. Reddys Lab 1235.00
Cipla 1322.45
Zydus Lifesciences 902.95
Lupin 2186.40
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×